SUGEN

Xcell Biosciences Announces New Scientific and Business Advisory Board

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Technology, Health, General Health, Oncology, Health Technology, Research, Software, Artificial Intelligence, Genetics, Science, PCR, Organization, EWF, Prostate cancer, Juno Therapeutics, Synthetic biology, Trex, University, CBO, Jak, Biology, Bayer, Investment, Therapy, Mountaineering, Intergalactic, AVATAR, SUGEN, Hematology, Bio-Rad Laboratories, Medicine

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.

Key Points: 
  • Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced the formation of a new scientific and business advisory board composed of some of the leading minds in the industry.
  • The board will provide valuable expertise to help the company achieve its goals in the therapeutics market.
  • Prior to Affini-T, Jak was head of health venture investments for Leaps by Bayer, a leading corporate venture fund.
  • Jak also served as CEO of CytoSen Therapeutics, where he developed natural killer immune cell therapies for oncology indications.

TOLREMO therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest

Retrieved on: 
Wednesday, September 20, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, KRAS, Gilead Sciences, SUGEN, University, Therapy, CBP, ARCH Venture Partners, Stanford University, Survival, University of California, Davis, Cancer, Pharmacokinetics, Coronavirus Scientific Advisory Board, AG, Drug resistance, Patient, EGFR, Biology, Health care, FDA, CHF, AR, Microbiology, Safety, Chair, Pharmaceutical industry, Doctor of Philosophy

TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million).

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million).
  • BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors.
  • Stepwise, TOLREMO will then advance to evaluating TT125-802 in combination with targeted therapies such as KRAS, EGFR or AR inhibitors in specific advanced solid tumor indications.
  • In addition, Francesco Hofmann, PhD, Head of R&D for Medical Care at Pierre Fabre Laboratories, joined TOLREMO's Scientific Advisory Board.

Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

Retrieved on: 
Tuesday, January 17, 2023
Carbon, Herbicide, Corporation, Pesticide, Entrepreneurship, ODM, Fertilizer, Royal commission, Seed, Transcription activator-like effector nuclease, Biotechnology, Canaccord Genuity, Transcription, Agriculture, Cellectis, Gene editing, USDA, Growth, SUGEN, Synthetic biology, Research, SAN, Sale, Science, Royalty Pharma, European Commission, Food security, Management, Biomatrix systems theory, CIBU-FM, S.A

ROSEVILLE, Minn. and SAN DIEGO, Jan. 17, 2023 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.

Key Points: 
  • The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.
  • Renewable Low-Carbon Ingredients: Gene editing is a key tool in the development of sustainable low-carbon ingredients that can replace fossil fuel-based ingredients and diesel fuel.
  • In addition, Cibus and Calyxt are both working with leading consumer product companies to develop more sustainable ingredients.
  • Under the terms of the merger agreement, Calyxt will issue shares of its common stock to Cibus shareholders in an exchange ratio such that upon completion of the merger, Calyxt shareholders will own approximately 5% of the combined company, subject to adjustments permitted by the merger agreement.

Syntax Announces Executive Transition

Retrieved on: 
Tuesday, January 17, 2023
Professional Services, Data Management, Technology, Software, Finance, Asset Management, Fintech, Database, FIS, Biotechnology, CIBU-FM, RBR Enterprises, SUGEN, Index, Research, Elena Shaddow, Royalty Pharma, Management, Syntax

He takes over as CEO from the company’s founder, Rory Riggs, who heads the Board of Directors as Executive Chairman.

Key Points: 
  • He takes over as CEO from the company’s founder, Rory Riggs, who heads the Board of Directors as Executive Chairman.
  • Since joining Syntax in 2021, Shaddow has been driving the company's transition from research and development to commercialization as a provider of a new generation of financial data powered by its patented Functional Information System (FIS®).
  • He founded Syntax in 2009 after observing inadvertent biases in financial indices that are also common in the design of human clinical trials.
  • Patrick is a strategic, results-driven leader, who is uniquely positioned to steer Syntax towards success in the years ahead.”
    As Executive Chairman, Riggs will lead the company’s Board of Directors and continue to work closely with Shaddow and the Syntax management team.

CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), SUGEN, Annual report, Development, Primary biliary cholangitis, Knowledge, PBC, Food and Drug Administration, U.S. Securities and Exchange Commission, Liver, GLOBE, Hepatitis, Liver disease, Fibrosis, Circulatory system, Research and development, Drug discovery, Priority, NASDAQ, Therapy, European Medicines Agency, Pfizer, Cornell University, Patient, Senior, CSO, Conditional sentence, Pharmaceutical industry, Medical device, Research

We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer.

Key Points: 
  • We are excited to announce the promotion of Chuck to President of Research and Development, in addition to his continuing role as Chief Scientific Officer.
  • Chuck joined CymaBay in 2007 and has served as Chief Scientific Officer since 2013.
  • It is a privilege to be given the opportunity to lead the talented and experienced R&D team at CymaBay.
  • From 2007 to 2013, he served as Senior Vice President, Research and Preclinical Development.

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Retrieved on: 
Wednesday, September 7, 2022
MedImmune, AstraZeneca, Pharmacia, Rensselaer Polytechnic Institute, Enzyme, Inflammation, University, Human, CEO, RNA, Cancer, IP Group, McMahon, CNS, Sunitinib, Global Partnership for Education, Therapy, Genetics, NASDAQ, BS, Doctor of Philosophy, Tufts University School of Medicine, FTI, Massachusetts Institute of Technology, Board, IPO, SUGEN, RME, Senior, STORM, METTL3, Biology, Company, Yale University, FDA, Biotechnology, Merck, Merck Group, Degenerative disease, Biochemistry, Drug discovery, Growth, Trial of the century, Patient, Pharmaceutical industry, Vaccine, IND, Pfizer

CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.

Key Points: 
  • CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.
  • Dr. Jerry McMahon added:"STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME.
  • Dr. McMahon was President and CEO of NASDAQ listed Harpoon Therapeutics, building the Company from early stage through to IPO, follow-on financings, and development collaborations.
  • STORM Therapeutics (STORM) is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Retrieved on: 
Wednesday, September 7, 2022
MedImmune, AstraZeneca, Pharmacia, Rensselaer Polytechnic Institute, Enzyme, Inflammation, University, Human, CEO, RNA, Cancer, IP Group, McMahon, CNS, Sunitinib, Global Partnership for Education, Therapy, Genetics, NASDAQ, BS, Doctor of Philosophy, Tufts University School of Medicine, FTI, Massachusetts Institute of Technology, Board, IPO, SUGEN, RME, Senior, STORM, METTL3, Biology, Company, Yale University, FDA, Biotechnology, Merck, Merck Group, Degenerative disease, Biochemistry, Drug discovery, Growth, Trial of the century, Patient, Pharmaceutical industry, Vaccine, IND, Pfizer

CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.

Key Points: 
  • CAMBRIDGE, England, Sept. 7, 2022 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.
  • Dr. Jerry McMahon added:"STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME.
  • Dr. McMahon was President and CEO of NASDAQ listed Harpoon Therapeutics, building the Company from early stage through to IPO, follow-on financings, and development collaborations.
  • STORM Therapeutics (STORM) is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

AnHeart Therapeutics Appoints Dr. Shuanglian (Lian) Li as Chief Medical Officer (US)

Retrieved on: 
Monday, August 1, 2022
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, SUGEN, Acquisition, University, Biogen, Drug, ROS1, EGFR, Therapy, Multimedia, TKI, Cancer, Takeda, Takeda Pharmaceutical Company, University of California, San Francisco, Pfizer, Drug development, ARIAD Pharmaceuticals, Peking University Health Science Center, FDA, NSCLC, Company, Senior, Patient, Precision medicine, Head, SVP, Doctor of Philosophy, Medical school, AXL, Pharmacy, Toxicology, Pharmaceutical industry, Medical device, Pharmacology

AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced the appointment of Shuanglian (Lian) Li, M.D., Ph.D., as the companys Senior Vice President and Chief Medical Officer (US).

Key Points: 
  • AnHeart Therapeutics (AnHeart), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, today announced the appointment of Shuanglian (Lian) Li, M.D., Ph.D., as the companys Senior Vice President and Chief Medical Officer (US).
  • View the full release here: https://www.businesswire.com/news/home/20220801005062/en/
    Shuanglian (Lian) Li, M.D., Ph.D., Senior Vice President and Chief Medical Officer (US), AnHeart Therapeutics.
  • Prior to its acquisition by Takeda, Dr. Li was Medical Director at ARIAD Pharmaceuticals and the medical lead for several oncology programs.
  • AnHeart Therapeutics (AnHeart) is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel or next-generation precision oncology therapeutics with high unmet medical needs.

Actym Therapeutics Announces Significant Expansion of Senior Leadership

Retrieved on: 
Thursday, May 12, 2022
UC, Stanford University, Strategic planning, Chemical engineering, School, Dartmouth, UCSF, University, Business economics, Division, Cancer, Agency for Toxic Substances and Disease Registry, Tuck School of Business, Janssen Pharmaceuticals, Investment, Oregon State University, Therapy, Control, National Center for Manufacturing Sciences, Om, Johnson & Johnson, Hardpan, Board, University of California, Santa Barbara, Icahn School of Medicine at Mount Sinai, Business, SUGEN, Air force, Department, Company, Doctor of Philosophy, Director, IV, Strategy, FDA, Biotechnology, CBO, CA, Shantha Biotechnics, A-DNA, R, Economics, Patient, Business development, Sutro Biopharma, Pharmacology, M.B.A, MSAT, Bayer, United, Gilead Sciences, CEO, Pharmaceutical industry, Management, Vaxart, Technology, Symphogen

BERKELEY, Calif., May 12, 2022 /PRNewswire/ -- Actym Therapeutics,a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team.

Key Points: 
  • BERKELEY, Calif., May 12, 2022 /PRNewswire/ -- Actym Therapeutics,a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team.
  • "On behalf of the Executive Leadership Team and the Board of Directors, we are thrilled to welcome this accomplished group of leaders to Actym."
  • As Vice President, Technical Operations, Omkar will serve as a member of the Actym Executive Leadership Team and will be responsible for all aspects of technical development, manufacturing, analytical development, and quality at Actym.
  • Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer.